| Diabetes Mellitus, Non-Insulin-Dependent
Jardiance vs Jentadueto
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jardiance vs Jentadueto with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJentadueto has a higher rate of injection site reactions vs Jardiance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jentadueto but not Jardiance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jardiance
Jentadueto
At A Glance
Oral
Once daily
SGLT2 inhibitor
Oral
Twice daily
DPP-4 inhibitor / biguanide
Indications
- Heart failure
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Heart failure, Chronic Kidney Diseases 10 mg orally once daily in the morning, taken with or without food.
Diabetes Mellitus, Non-Insulin-Dependent 10 mg orally once daily in the morning, taken with or without food; may increase to 25 mg once daily in patients tolerating 10 mg for additional glycemic control.
Diabetes Mellitus, Non-Insulin-Dependent Individualized dosing orally twice daily with meals; starting at 2.5 mg linagliptin/500 mg metformin HCl twice daily for metformin-naive patients, maximum 2.5 mg linagliptin/1,000 mg metformin HCl twice daily; contraindicated if eGFR <30 mL/min/1.73 m2; initiation not recommended if eGFR 30-45 mL/min/1.73 m2.
Contraindications
- Hypersensitivity to empagliflozin or any excipient in JARDIANCE (reactions such as angioedema have occurred)
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to linagliptin, metformin, or any excipient in JENTADUETO
Adverse Reactions
Most common (>=2%) Urinary tract infection, female genital mycotic infections, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, male genital mycotic infections, nausea
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypoglycemia (with insulin or sulfonylurea), hypersensitivity reactions
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, skin reactions (rash, urticaria)
Most common (>=5%) Nasopharyngitis, diarrhea (combination); diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache (metformin initiation)
Serious Lactic acidosis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, rash, cholestatic/hepatocellular/mixed liver injury
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; it also reduces sodium reabsorption, which may increase tubuloglomerular feedback, reduce intraglomerular pressure, and lower cardiac pre- and afterload.
Linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin release and reducing glucagon secretion; metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jardiance
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Jentadueto
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Jardiance
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Jentadueto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Jardiance
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Jentadueto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Jardiance Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Jentadueto.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JardianceView full Jardiance profile
JentaduetoView full Jentadueto profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.